Anti-cancer potential of liver mesenchymal stem cell conditioned media against Ehrlich ascites carcinoma bearing mice

This research evaluates the antitumor outcome of liver mesenchymal stem cell conditioned media (L-MSCs-CM) versus Ehrlich ascites carcinoma-bearing mice. A total of forty mice were categorized into four groups normal control group, and the further 3 groups that were injected intraperitoneally with 1x106 EAC cells, including the Ehrlich ascites carcinoma group, Methotrexate group that administrated with methotrexate (MTX), and liver mesenchymal stem cell treated group mice that was administrated with L-MSCs-CM. The findings demonstrated that the injection of L-MSCS CM revealed a significant reduction in EAC cell count and tumor ascites volume. Furthermore, a significant reduction in malondialdehyde level and expression of Bcl-2 in the liver and kidney tissue contrasted to the EAC group. Furthermore, there was a significant elevation in total antioxidant capacity and caspase-3 expression level in the liver and kidney contrasted to the EAC group. Many histopathological alterations were observed within the hepatic and renal tissue of the EAC group on the other hand, treatment with L-MSCs-CM restore the hepatic and renal tissue's normal histological architectures. The results indicated that L-MSCs-CM has an antitumor effect against EAC through inhibiting angiogenesis and inducing apoptosis.